Press Releases InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids December 3, 2020 Read More » InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects November 25, 2020 Read More » InMed Announces Election of Directors November 25, 2020 Read More » InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics November 18, 2020 Read More » InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering November 16, 2020 Read More » InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results November 13, 2020 Read More » InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol “INM” November 12, 2020 Read More » InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020 November 5, 2020 Read More » InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020 November 4, 2020 Read More » InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects September 24, 2020 Read More » InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing September 22, 2020 Read More » InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update September 8, 2020 Read More » InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020 September 2, 2020 Read More » InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755 July 7, 2020 Read More » InMed Announces Completion of Share Consolidation June 30, 2020 Read More » InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System June 24, 2020 Read More » InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation June 19, 2020 Read More » InMed Releases CBN Preclinical Results in Glaucoma May 27, 2020 Read More » InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family May 19, 2020 Read More » InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update May 14, 2020 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids December 3, 2020 Read More »
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects November 25, 2020 Read More »
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics November 18, 2020 Read More »
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering November 16, 2020 Read More »
InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results November 13, 2020 Read More »
InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol “INM” November 12, 2020 Read More »
InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020 November 5, 2020 Read More »
InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020 November 4, 2020 Read More »
InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects September 24, 2020 Read More »
InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update September 8, 2020 Read More »
InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020 September 2, 2020 Read More »
InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System June 24, 2020 Read More »
InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation June 19, 2020 Read More »
InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update May 14, 2020 Read More »